

Name of the Issuer:		Metropolis Healthcare Limited	Last updated on	23-Jun-22												
1	Type of Issue (IPO / FPO)		IPO													
2	Issue Size (Rs. Million)*		12,042.88													
	- Fresh Issue Size (Rs. Millions)		0.00													
	- Offer for Sale Component (Rs. Millions)		12,042.88													
	*Source: Final post issue report dated April 16, 2019															
3	Grade of issue along with name of the rating agency															
	Name	Not Applicable														
	Grade	Not Applicable														
4	Subscription Level (Number of times)		3.68*													
	Source: Final post issue report dated April 16, 2019															
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges															
	<table><tr><th>Particulars</th><th>%</th></tr><tr><td>(i) allotment in the issue ⁽¹⁾</td><td>20.44%</td></tr><tr><td>(ii) at the end of 1st Quarter immediately after the listing</td><td>21.71%</td></tr><tr><td>(iii) at the end of 1st FY (March 31, 2020)</td><td>22.24%</td></tr><tr><td>(iv) at the end of 2nd FY (March 31, 2021)</td><td>42.97%</td></tr><tr><td>(v) at the end of 3rd FY (March 31, 2022)</td><td>38.11%</td></tr></table>				Particulars	%	(i) allotment in the issue ⁽¹⁾	20.44%	(ii) at the end of 1st Quarter immediately after the listing	21.71%	(iii) at the end of 1st FY (March 31, 2020)	22.24%	(iv) at the end of 2nd FY (March 31, 2021)	42.97%	(v) at the end of 3rd FY (March 31, 2022)	38.11%
Particulars	%															
(i) allotment in the issue ⁽¹⁾	20.44%															
(ii) at the end of 1st Quarter immediately after the listing	21.71%															
(iii) at the end of 1st FY (March 31, 2020)	22.24%															
(iv) at the end of 2nd FY (March 31, 2021)	42.97%															
(v) at the end of 3rd FY (March 31, 2022)	38.11%															
	*QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.															
	(1) Source: Basis of Allotment. Includes allotment to Anchor Investors															
6	Financials of the issuer															
	(In Rs. Millions)															
	Parameters	1st FY (March 31, 2020)	2nd FY (March 31, 2021)*	3rd FY (March 31, 2022)*												
	Income from operations	8,564.05	9979.87	12283.36												
	Net Profit for the period	1,275.52	1822.69	2123.69												
	Paid-up equity share capital	101.26	102.33	102.34												
	Reserves excluding revaluation reserves	5,133.70	6963.77	8759.63												
	*Financials not disclosed as reporting for the relevant fiscal year has not been completed.															
7	Trading Status in the scrip of the issuer															
	Company's Equity Shares are listed on both the BSE Limited and National Stock Exchange of India Limited															
	The Shares have not been suspended or delisted.															
	Particulars	Status														
	(i) at the end of 1st FY (March 31, 2020)	Frequently Traded														
	(ii) at the end of 2nd FY (March 31, 2021)*	Frequently Traded														
	(iii) at the end of 3rd FY (March 31, 2022)*	Frequently Traded														
	*Trading status not disclosed as the relevant fiscal year has not been completed.															
8	Change in Directors of issuer from the disclosures in the offer document															
	Particulars	Name of the Director	Appointed / Resigned													
	(i) at the end of 1st FY (March 31, 2020)	Mr. Mihir Jagdish Doshi	Resigned													
	(ii) at the end of 2nd FY (March 31, 2021)	Mrs. Anita Ramchandran	Appointed													
	(iii) at the end of 3rd FY (March 31, 2022)	Hemant Sachdev	Appointed													
	* Changes in Directors not disclosed as the relevant fiscal year has not been completed.															
9	Status of implementation of project/ commencement of commercial production															
	(i) as disclosed in the offer document	Not applicable														
	(ii) Actual implementation	Not applicable														
	(iii) Reasons for delay in implementation, if any	Not applicable														
10	Status of utilization of issue proceeds															
	(i) as disclosed in the offer document	Not applicable														
	(ii) Actual utilization	Not applicable														

(iii) Reasons for deviation, if any

Not applicable

11 Comments of monitoring agency

(a) Comments on use of funds	Not applicable
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data

Issue Price (Rs.): 880
Designated Stock Exchange: BSE
Listing Date: 15-Apr-19

Price parameters	At close of listing day (April 15, 2019)	At close of 30th calendar day from listing day (May 14, 2019) ⁽¹⁾	At close of 90th calendar day from listing day (July 13, 2019) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2020) ⁽²⁾⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on BSE	959.55	912.85	1067.45	1,286.25	1,990.70	912.85
BSE Sensex	38,905.84	37318.53	38736.23	29,468.49	41,952.63	25,981.24
S&P BSE Healthcare	14,505.67	13452.29	12923.39	12,148.57	14,535.10	11,007.36

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2021) ⁽³⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2022) ⁽³⁾		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	2,241.05	2,344.95	1,150.00	2,036.70	3,473.60	1,861.40
BSE Sensex	49,509.15	52,516.76	27,500.79	58,568.51	61,765.59	47,705.80
S&P BSE Healthcare	21,328.21	22,464.34	11,878.39	24,303.83	26,879.99	21,528.53

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on closing prices

(4) Pricing data not disclosed as the relevant fiscal year has not completed

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2020)	At the end of 2nd FY (March 31, 2021)	At the end of 3rd FY (March 31, 2022)
EPS (Basic)	Issuer:			
	Consolidated (Basic)	20.61	25.36	41.87
	Peer Group:			
	Dr. Lal Pathlabs Limited	20.85	27.42	41.70
	Industry Avg:	20.85	27.42	35.33
NAV per share	Issuer:			
	Consolidated	83.58	202.66	138.23
	Peer Group:			
	Dr. Lal Pathlabs Limited	96.93	123.99	153.10
	Industry Avg:	96.93	123.99	153.10
Price to Earnings Ratio (P/E)	Issuer:			
	Based on Consolidated Basic EPS	42.70	50.72	62.30
	Peer Group:			
	Dr. Lal Pathlabs Limited	50.57	51.12	76.63
	Industry Avg:	50.57	51.12	76.63
	Issuer:			
	Consolidated	24.66%	24.37%	25.95%
				23.96%

RoNW(%)	Peer Group:			
	Dr. Lal Pathlabs Limited	21.61%	22.04%	23.17%
	Industry Avg:	21.61%	22.04%	23.17%
				23.23%

Notes:
(1) Sourced from Prospectus dated April 8, 2019.
(2) Information not provided as the relevant fiscal year has not completed
Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:
(i) Basic Earnings per Share (Rs.) = Restated net profit after tax and adjustments, attributable to equity shareholders / Weighted average no. of equity shares outstanding during the year.
Earnings per share calculations are in accordance with the notified Ind AS 33 'Earnings per share' notified accounting standard by the Companies (Indian Accounting Standards) Rules of 2015 (as amended).
(ii) Net Asset Value Per Equity Share = Net worth as per the Restated Summary Statements / Number of equity shares outstanding as at the end of year/period.
(iii) P/E - Closing Market Price as of relevant fiscal year end / Basic Consolidated EPS
(iv) Return on Net Worth (%) = Restated net profit after tax, available for equity shareholders / Restated net worth at the end of the year.

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
30-Sep-19	Company has informed the Exchanges regarding the acquisition of 4 laboratories by Desai Metropolis Healthcare Services Private Limited, a wholly owned subsidiary of the Company.
11-Nov-19	Company has informed the Exchanges regarding the resignation of Mr. Tushar Karnik, CFO of the Company and appointment of Mr. Rakesh Agarwal as the new CFO
29-Nov-19	Company has informed the Exchanges regarding the resignation of Mr. Jayant Prakash, Compliance Officer and Company Secretary of the Company.
7-Dec-19	Company has informed the Exchanges regarding the appointment of Ms. Varsha Hardasani, as interim Compliance Officer of the Company.
13-Dec-19	Company has informed the Exchanges that the Company has won the Patient Experience Team of the Year Award on December 11, 2019 by Patient Experience Excellence Awards 2019 held at hotel Shangri La, New Delhi
16-Jan-20	Company has informed the Exchanges regarding acquisition of Equity Shares of Shraddha Diagnostic Centre (I) Private Limited.
16-Jan-20	Company has informed the Exchanges that the Board, at their meeting held on February 06, 2020, transacted the following items of business(corporate actions): 1. Declared an interim dividend of Rs.8/- per equity share; 2. Fixed February 15, 2020 as record date for interim dividend and February 24, 2019 as payment date;
16-Jan-20	Company has informed the Exchanges regarding the appointment of Ms. Poonam Tanwani, as new Compliance Officer and Company Secretary of the Company.
12-Feb-20	Company has informed the Exchanges that CEO of the Company, Ms. Ameera Shah, has won the CEO of the Year-Next Gen award at the CEO Awards 2019 organised by CNBC AWAAZ
2-Jul-20	The Company vide letter dated 16th January, 2020 informed the Exchange(s) regarding the decision of Company to acquire 51% stake at a consideration of Rs.9,36,30,000/- in Shraddha Diagnostic Centre (I) Private Limited from its Promoters (Seller) vide Shareholders' Agreement and Share Purchase dated 16th January, 2020 entered between the Company, SDCIPL and its promoters. The closure of transaction was subject, to certain conditions precedent as specified in the Share Purchase Agreement (SPA) to be fulfilled on or before the amended long stop date, as per the supplemental share purchase agreement. The promoters of SDCIPL have conveyed that they cannot fulfil certain conditions precedent due to which the closing could not be completed, which is a breach of Warranty. Therefore, the promoters of SDCIPL have communicated to the Company their intent to terminate the said SPA and accordingly the proposed acquisition stands closed.
11-Aug-20	Board of Directors of the Company at their meeting held on August 11, 2020 through video conferencing have inter-alia: 1. Approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter ended June 30, 2020 and took note of the Limited Review Report issued by the Statutory Auditors of the Company on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter ended June 30, 2020. 2. Approved the acquisition of balance Equity stake of 35% i.e. 10,50,000 Equity shares of Rs.10/- each in Metropolis Histoexpert Digital Services Private Limited ('Histoexpert'). 3. Approved the acquisition of balance Equity stake of 49% i.e. 8,894 Equity shares of Rs.10/- each in Raj Metropolis Healthcare Private Limited ('Raj Metropolis').
5-Nov-20	Company has informed that it has successfully acquired the balance stake of 49% in Raj Metropolis Healthcare Private Limited.
9-Nov-20	Company has informed the Exchange regarding a press release dated November 09, 2020, titled "Metropolis Healthcare wins the Diagnostic Company of the Year Award organized by Frost & Sullivan

11-Nov-20	<p>Company has informed the Exchange that the Board of Directors of the Company at their meeting have inter-alia:</p> <p>a. Approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and half-year ended September 30, 2020 and took note of the Limited Review Report issued by the Statutory Auditors of the Company on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and half-year ended September 30, 2020;</p> <p>b. Noted the inadvertent delay in completion of the acquisition of the balance stake of 35% in Metropolis Histoexpert Digital Services Private Limited due to the lockdown imposed in Netherlands, the headquarter of Koninklijke Philips N.V., the J.V. partner</p>
12-Nov-20	Company has informed the Exchange regarding Allotment of 177887 Shares pursuant to ESOP Scheme.
17-Jan-21	<p>Company has informed that the Board of Directors of Metropolis Healthcare Limited (the Company) at their meeting held today, have inter-alia considered and approved:</p> <p>1. Increase in limits available with the Company to provide loan, guarantee to any person or Body Corporate or make investment in any Body Corporate under Section 186 of the Companies Act, 2013 from Rs.500 Crores to Rs.1200 Crores, subject to the approval of the shareholders.</p> <p>2. Acquisition of entire 100% stake in Dr. Ganesan's Hitech Diagnostic Centre Private Limited and its subsidiary ('Hitech') from its existing promoters / shareholders for a consideration to be discharged partly by Cash and partly by issuance of equity shares of the Company as per the details mentioned in the Annexures.</p> <p>3. Issuance of up to 495000 equity shares of face value Rs. 2/- each fully paid up of the Company at a price to be arrived on the Relevant Date, as per Regulation 164 of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, to the promoters / shareholders of Hitech on a Preferential basis for consideration other than cash subject to approval of the shareholders. Pursuant to the completion of the acquisition, Hitech will become a wholly owned subsidiary of the Company.</p>
17-Jan-21	Company has informed the Exchange regarding a press release dated January 17, 2021, titled 'Metropolis Healthcare to acquire Hitech Diagnostic Centre to
10-Feb-21	<p>Company has informed that the Board of Directors of the Company at their meeting held today have inter-alia:</p> <p>i. Approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and nine months ended December 31, 2020 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and nine months ended December 31, 2020.</p> <p>ii. Approved the re-appointment of Ms. Ameera Sushil Shah as the Managing Director, for a period of five years with effect from March 18, 2021, as per the recommendation of the Nomination and Remuneration Committee, subject to approval of members of the Company at the ensuing Annual General Meeting.</p> <p>iii. Approved and declared payment of Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per equity share on the Face Value Rs. 2 (Rupees Two only) each for the financial year 2020- 2021. The interim dividend will be paid to the members whose names appear in the Register of Members / Register of beneficiaries as on the 'Record Date' i.e. February 19, 2021. The Interim Dividend will be paid to the shareholders within 30 days of declaration.</p>
10-Feb-21	Company has informed the Exchange regarding Allotment of 10000 Shares pursuant to ESOP scheme
30-Mar-21	Company has informed the Exchange regarding a press release dated March 30, 2021, titled 'Ameera Shah awarded EY Entrepreneur of the Year in life science and
27-May-21	Company has informed that the Board of Directors of the Company at their meeting held today have inter-alia:
27-May-21	Company has informed the Exchange regarding Allotment of 12100 Shares under ESOP scheme
8-Jul-21	Company has informed the Exchange regarding Allotment of 25416 Shares under ESOP scheme
10-Jul-21	<p>Company has The Board of Directors of Metropolis Healthcare Ltd ("the Company") had approved the acquisition of Dr. Ganesan's Hitech Diagnostic Centre Private Limited and its subsidiary Centralab Healthcare Services Private Limited on 17th January 2021 in a combination of cash and equity shares deal. To achieve the closure of the transaction the Company took shareholder and other necessary approvals. However, through delays in the completion of the Sellers' obligations under the Share Purchase Agreement ("SPA"), the transaction as contemplated under the SPA was initiated but has not been wholly consummated till date. In the interim, the statutory approvals obtained by the Company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained.</p> <p>The Company, since the 3rd/4th week of April 2021, through various discussions and correspondences has been trying to conclude the said transaction with the Sellers under the SPA. A letter was also issued on 5th July 2021 to the Sellers asking them to fulfil their obligations under the SPA and communicate to the Company on the said transaction, failing which it will be considered as a confirmation by the Sellers of their intention to terminate the transaction without prejudicing the rights of the Company under the SPA. In the view of no communication from the Sellers to the letter issued on 5th July 2021, it can be assumed that the Sellers are not intending to close the transaction. The Company is presently evaluating its rights, and the various routes available for their enforcement, and will accordingly take appropriate actions on this matter.</p>
6-Aug-21	<p>Company has informed that the Board of Directors of the Company at their meeting have inter-alia:</p> <p>1. Approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter ended June 30, 2021 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter ended June 30, 2021;</p> <p>2. Took note of the recommendation of the Audit Committee and subject to requisite consents / approvals, approved the Scheme of merger by absorption of Bokil Golwilkar Metropolis Healthcare Private Limited and Desai Metropolis Health Services Private Limited and Dr. Patel Metropolis Healthcare Private Limited and Lab One Metropolis Healthcare Services Private Limited and Micron Metropolis Healthcare Private Limited and R. V. Metropolis Diagnostic & Health Care Center Private Limited and Raj Metropolis Healthcare Private Limited and Sudharma Metropolis Health Services Private Limited ("Transferor Companies") with the Company and their respective Shareholders ("Scheme") under the provisions of sections 230 to 232 of the Companies Act, 2013;</p> <p>3. Approved fund raise of up to Rs. 15,000 million by way of private placement or preferential issue or public issue or through any other permissible mode and/or combination thereof, including by way of qualified institutions placement, in accordance with applicable laws and subject to appropriate sanctions, permission and approvals including shareholders' approval and statutory and regulatory approvals, as may be required;</p> <p>4. Approved the Postal ballot Notice in terms of Section 110 of the Companies Act, 2013 read with Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014 for seeking shareholders' approval;</p> <p>5. Approved the acquisition of the balance Equity stake of 35% i.e. 10,50,000 Equity shares of Rs.10/- each in Metropolis Histoexpert Digital Services Private Limited ('Histoexpert') pursuant to a fresh valuation report issued by M/s. R.V. Shah & Associates, Chartered Accountants;</p> <p>6. Approved the appointment of Ms. Simmi Singh Bisht having Membership Number ACS 23360 as the Company Secretary and Compliance Officer of the Company (designated as Head - Legal and Secretarial) with effect from August 6, 2021 and took note of the cessation of Mr. Danish Allana as the Interim Compliance Officer of the Company with effect from August 6, 2021;</p>
6-Aug-21	Company has informed the Exchange regarding Allotment of 15800 Shares under ESOP scheme
11-Oct-21	Company has informed the Exchange regarding allotment of 364 securities pursuant to ESOP/ESPS at its meeting held on October 11, 2021

20-Oct-21	Company has informed that CRISIL, a Credit Rating Agency has revised its outlook on the rating from 'CRISIL AA-/Stable' to 'CRISIL AA-/Positive' on the Non-Convertible Debentures and the long-term loan facility of the Company and has also reaffirmed its 'CRISIL A1+' rating to the short-term facility of the Company.
22-Oct-21	Company has informed that in continuation to our earlier intimation dated October 15, 2021 having reference no. MHL/Sec&Legal/2021-22/49 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that Metropolis Healthcare Limited ("the Company") has completed the acquisition of 100% stake of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ("Hitech") along with its subsidiary Centralab Healthcare Services Private Limited ("Centralab") on October 22, 2021 for a cash consideration of Rs.636 Crores (Six Hundred and Thirty-Six Crores Only) as per the terms and conditions of the Share Purchase Agreement including amendments thereof entered between the Company and the sellers. Post completion of the aforesaid acquisition, "Hitech" and "Centralab" has become wholly-owned subsidiary and step down wholly owned subsidiary respectively of the Company.
10-Nov-21	Company has informed that the Board of Directors of the Company at their meeting held today have inter-alia approved the Unaudited Standalone and
5-Jan-22	Company has informed the Exchange regarding Allotment of 1626 Shares under ESOP scheme
	Company has informed that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, February 11, 2022 through Video Conferencing to inter-alia: i. Consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021. ii. Consider the proposal for declaration of an Interim Dividend for the Financial Year 2021-22, if any. The Record date for the purpose of determining eligibility of Members entitled to receive Interim Dividend, if any, shall be Tuesday, February 22, 2022 subject to the approval of the Board.
11-Feb-22	Company has informed that the Board of Directors of the Company at their meeting held today have inter-alia:
1-Apr-22	Company has informed the Exchange about Intimation for Voluntary Liquidation of Dr. Ganesan Hitech Diagnostic Centre Private Limited ("Hitech"), Subsidiary of the
14-Apr-22	Company has informed the Exchange regarding Allotment of 128 Shares under ESOP scheme
24-May-22	Company has informed the Exchange about Board Meeting held on 24-May-2022 to consider financial statements for the period ended March 2022 and and
4-Jun-22	Company has informed the Exchange about Intimation for distribution of business of Dr. Ganesan Hitech Diagnostic Centre Private Limited ("Hitech"), Subsidiary of